Drug intelligence / Profile preview

SKYCellflu trivalent

Development stage: Unknown
Lead developer: SK bioscience
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**SKYCellflu trivalent** is a cell culture-derived, trivalent inactivated seasonal influenza vaccine developed by SK Chemicals and subsequently developed and manufactured by SK bioscience. It contains purified inactivated influenza-virus surface antigens from two influenza A strains and one influenza B strain, and is administered by intramuscular injection for prevention of influenza caused by vaccine-matched influenza A and B viruses. The vaccine is produced without fertilized eggs and has received World Health Organization prequalification as a trivalent cell culture-based influenza vaccine.

Brand names: SKYCellfluSKYCellflu 3-valentSKYCellflu3-valentSKYCellflu-3-valentSKYCellflu inj.SKYCellflu Multi inj.SKYCellflu trivalent

Beyond the preview

Go deeper on SKYCellflu trivalent.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKYCellflu trivalent.

Explore the full profile